Cargando…

Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Struble, Evi B., Rawson, Jonathan M. O., Stantchev, Tzanko, Scott, Dorothy, Shapiro, Marjorie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224075/
https://www.ncbi.nlm.nih.gov/pubmed/37242780
http://dx.doi.org/10.3390/pharmaceutics15051538
_version_ 1785050091301634048
author Struble, Evi B.
Rawson, Jonathan M. O.
Stantchev, Tzanko
Scott, Dorothy
Shapiro, Marjorie A.
author_facet Struble, Evi B.
Rawson, Jonathan M. O.
Stantchev, Tzanko
Scott, Dorothy
Shapiro, Marjorie A.
author_sort Struble, Evi B.
collection PubMed
description Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research.
format Online
Article
Text
id pubmed-10224075
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102240752023-05-28 Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies Struble, Evi B. Rawson, Jonathan M. O. Stantchev, Tzanko Scott, Dorothy Shapiro, Marjorie A. Pharmaceutics Review Viral diseases represent a major public health concerns and ever-present risks for developing into future pandemics. Antiviral antibody therapeutics, either alone or in combination with other therapies, emerged as valuable preventative and treatment options, including during global emergencies. Here we will discuss polyclonal and monoclonal antiviral antibody therapies, focusing on the unique biochemical and physiological properties that make them well-suited as therapeutic agents. We will describe the methods of antibody characterization and potency assessment throughout development, highlighting similarities and differences between polyclonal and monoclonal products as appropriate. In addition, we will consider the benefits and challenges of antiviral antibodies when used in combination with other antibodies or other types of antiviral therapeutics. Lastly, we will discuss novel approaches to the characterization and development of antiviral antibodies and identify areas that would benefit from additional research. MDPI 2023-05-19 /pmc/articles/PMC10224075/ /pubmed/37242780 http://dx.doi.org/10.3390/pharmaceutics15051538 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Struble, Evi B.
Rawson, Jonathan M. O.
Stantchev, Tzanko
Scott, Dorothy
Shapiro, Marjorie A.
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
title Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
title_full Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
title_fullStr Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
title_full_unstemmed Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
title_short Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
title_sort uses and challenges of antiviral polyclonal and monoclonal antibody therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224075/
https://www.ncbi.nlm.nih.gov/pubmed/37242780
http://dx.doi.org/10.3390/pharmaceutics15051538
work_keys_str_mv AT strubleevib usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies
AT rawsonjonathanmo usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies
AT stantchevtzanko usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies
AT scottdorothy usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies
AT shapiromarjoriea usesandchallengesofantiviralpolyclonalandmonoclonalantibodytherapies